Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations
February 18 2021 - 8:00AM
Business Wire
Xeris Pharmaceuticals, Inc.
(Nasdaq: XERS), a specialty pharmaceutical company leveraging its
novel technology platforms to develop and commercialize
ready-to-use injectable and infusible drug formulations, today
announced that Paul R. Edick, Chairman and Chief Executive Officer
of Xeris Pharmaceuticals, will present an overview of the Company
at the following upcoming investor conferences:
- SVB Leerink Annual Global Healthcare Conference: Friday,
February 26, 2021 at 10:40 am ET
- HC Wainwright Global Life Sciences Conference: on-demand
beginning at 7:00 am ET on March 9, 2021
- Oppenheimer 31st Annual Healthcare Conference: Tuesday, March
16, 2021 at 11:20 am ET
The presentations can be accessed by visiting ‘Upcoming Events’
in the Investors section on the Company's website at
www.xerispharma.com.
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company
delivering innovative solutions to simplify the experience of
administering important therapies that people rely on every day
around the world.
With a novel technology platform that enables ready-to-use,
room-temperature stable formulations of injectable and infusible
therapies, the company is advancing a portfolio of solutions in
various therapeutic categories, including its first commercial
products, Gvoke® in the U.S. and Ogluo™ in Europe. Its proprietary
XeriSol™ and XeriJect™ formulation technologies have the potential
to offer distinct advantages over conventional product
formulations, including eliminating the need for reconstitution,
enabling long-term, room-temperature stability, significantly
reducing injection volume, and eliminating the requirement for
intravenous (IV) infusion. With Xeris’ technology, new product
formulations are designed to be easier to use by patients,
caregivers, and health practitioners and help reduce costs for
payers and the healthcare system.
Xeris is headquartered in Chicago, IL. For more information,
visit www.xerispharma.com, or follow Xeris on Twitter, LinkedIn, or
Instagram.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Xeris Pharmaceuticals, Inc., including
statements regarding the market and therapeutic potential of its
product candidates, expectations regarding clinical data or results
from planned clinical trials, the timing or likelihood of
regulatory approval and commercialization of its product
candidates, the timing or likelihood of expansion into additional
markets, the potential utility of its formulation platforms and
other statements containing the words "will," "would," "continue,"
and similar expressions, constitute forward-looking statements
within the meaning of The Private Securities Litigation Reform Act
of 1995. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important
factors, including, without limitation, impact of COVID-19 on its
business operations, its reliance on third-party suppliers for
Gvoke®, the regulatory approval of its product candidates, its
ability to market and sell its products, if approved, and other
factors discussed in the "Risk Factors" section of the most
recently filed Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission, as well as discussions of
potential risks, uncertainties, and other important factors in
Xeris’ subsequent filings with the Securities and Exchange
Commission. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Xeris expressly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
The Company intends to use the investor relations portion of its
website as a means of disclosing material non-public information
and for complying with disclosure obligations under Regulation
FD.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210218005146/en/
Xeris Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Sep 2023 to Sep 2024